Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Ximelagatran vs Warfarin for Stroke Prophylaxis in Atrial Fibrillation
NCT00206063Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Aug 1999
- Primary completion
- Jun 2004
- Modality
- Small Molecules, Modified Peptides
- Countries
- 9
01
Overview
A Phase 2 trial of ximelagatran in Atrial fibrillation (AFib), sponsored by AstraZeneca. Started Aug 1999; status: terminated.
02
Drugs
ximelagatran
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT00206063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00206063.